Saturday 17 October 2026
Export GRCE’s income statement to Excel — free account
Grace Therapeutics, Inc.
GRCE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 333.3% and free cash flow fell 78.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
1.89
0.06
−3.08%
Follow GRCE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
11.02 | 7.92 | 14.56 | 13.56 | |
Current Ratio |
11.47 | 8.10 | 14.96 | 13.89 | |
Net Debt/EBITDA |
0.86 | 5.65 | 7.63 | 6.67 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.20 | 1.44 | 0.96 | 3.35 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.71 | 0.74 | 0.72 | 0.74 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.19) | (0.10) | (0.13) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.19) | (0.10) | (0.13) | (0.20) | |
Cash per Share |
0.80 | 1.03 | 1.10 | 1.06 | |
Shareholders Equity per Share |
2.79 | 3.87 | 3.83 | 3.94 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.79 | 3.87 | 3.83 | 3.94 | |
Free Cash Flow |
(3.22) | (1.69) | (2.23) | (3.14) | |
Working Capital |
13.08 | 15.23 | 17.93 | 16.05 | |
Net Current Asset Value |
12.47 | 14.62 | 15.62 | 13.54 | |
| Other line items | |||||
Average Receivables |
0.02 | 0.07 | 0.16 | 0.22 | |
Average Payables |
1.78 | 2.04 | 1.63 | 1.96 | |
Average Assets |
59.94 | 69.32 | 64.86 | 65.96 | |
Average Common Equity |
55.88 | 65.25 | 58.52 | 59.48 |
Columns are period end dates